Sagimet Biosciences has been added to the Russell 3000 Index and the small-cap Russell 2000 Index as part of the 2026 Russell indexes reconstitution. The inclusion, effective June 29, automatically places the clinical-stage biopharmaceutical company in either the Russell 1000 or Russell 2000 and across value or growth tilt indexes. CEO David Happel said the milestone reflects the company's progress and noted that its lead drug candidate denifanstat, if approved, would be the first innovative oral treatment for acne vulgaris in patients 12 and older in more than forty years. Sagimet has capital to fund operations through 2028, including a planned Phase 3 clinical trial for denifanstat in acne.
Sagimet Biosciences Inc. Series A Common StockIndex inclusion is a financial/valuation event that can attract passive fund inflows and increase visibility.